Thyroid CancerNCT06158360
An Observational Study on Postoperative Symptoms After Thyroidectomy (POS-T)
An observational study of Thyroid Cancer, run by Ilsan Cha hospital at 3 sites in South Korea.
Trial summary
This observational study aimed to evaluate the safety and efficacy of postoperative management in patients with thyroid cancer who received subtotal or total thyroidectomy. Read more about this study
- Who is it for?
- Ages 19 years and older
- Conditions the study is for
- Thyroid Cancer
- How many people
- 500 participants
- Where
- 3 sitesSouth Korea
- Study dates
- 1 Dec 2023to 31 Dec 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients who have been diagnosed with thyroid cancer (KCD C73) according to the ICD-10 International Classification of Diseases and have been recommended for postoperative management treatment by a physician or acupuncturist
Who may be able to join
- 19 years of age or older
- Those who have been confirmed to have a malignant tumor of the thyroid gland by biopsy or imaging
- Subjects who have undergone partial thyroidectomy or total resection within 1 month
- Those who have agreed to the implementation of Chinese medicine treatment
- The Eastern Cooperative Oncology Group(ECOG) performance status 0-3
- Those who understand the content of the study and agree to participate in the study
Who cannot join
- ○ When it is judged that other diseases other than cancer (dementia, cerebrovascular disease, severe organ failure, etc.) may have a significant effect on the decline of physical function
- When it is judged that the life expectancy is less than 3 months and sufficient follow-up cannot be carried out
- When emergency or major surgery or surgical intervention is required that takes precedence over postoperative treatment
- Pregnant and lactating women
- Other researchers who are judged to be unsuitable for research
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
South Korea3 sites, 3 recruiting
- Recruiting
Bundang Cha Hospital
Gyeonggi-do
Seongse Son, Dr., 010-7507-1070, sonsungse@chamc.co.kr
- Recruiting
Ilsan Cha Hospital
Gyeonggi-do
Jee Young Lee, Doctor, 082-31-782-3113, happiade@chamc.co.kr
- Recruiting
Gangnam Cha Hospital
Seoul
Chan-seok Yoon, Dr., 010-8773-2065, yoondoc@chamc.co.kr
About this study
Official title: A Prospective Multi-centered Observational Study on Postoperative Symptoms After Thyroidectomy (POS-T) in Patients With Thyroid Cancer
This observational study aimed to evaluate the safety and efficacy of postoperative management in patients with thyroid cancer who received subtotal or total thyroidectomy.
Read the detailed description
- Characteristic analysis of improvement in quality of life and symptoms after surgery in cancer patients
- Multifaceted symptom evaluation of cancer patients visiting medical institutions
- Evaluation of effectiveness and safety of treatment for postoperative symptoms in thyroid cancer patients
- Analysis of the effectiveness and prognosis of cancer-related treatment for each patient with cancer
- Analysis of prognostic factors for disease-free survival and overall survival of cancer patients
Among adult men and women aged 19 years or older who have been diagnosed with thyroid cancer, who have undergone partial or total thyroidectomy and visited the hospital for postoperative management, the characteristics of the visiting patient, quality of life, characteristics of cancer-related symptoms, and treatment effectiveness, We intend to conduct a prospective observational study to evaluate safety and its relationship with prognosis. In addition, we aim to form the basis for follow-up research through the establishment of an Oriental medicine cancer cohort and database.
- Conditions
- Thyroid Cancer
- Medical subject headings
- Thyroid Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
THYCA-QoL score at the time of discharge (1w) of hospitalization performed for postoperative management purposes
The THYCA-QoL is a health-related quality of life questionnaire developed for thyroid cancer and thyroid cancer survivors using methodologically proven standard guidelines and validated questionnaires to improve symptoms, treatment, follow-up and disease experience in thyThe THYCA-QoL is a health-related quality of life questionnaire developed for thyroid cancer and thyroid cancer survivors using methodologically proven standard guidelines and validated questionnaires to improve symptoms, treatment, follow-up and disease experience in thyroid cancer survivors. roid cancer survivors.
Measured: At the end of week 1(each cycle is 7days)
Secondary outcomes (8)
Change in THYCA-QoL over time series
The THYCA-QoL is a health-related quality of life questionnaire developed for thyroid cancer and thyroid cancer survivors using methodologically proven standard guidelines and validated questionnaires to improve symptoms, treatment, follow-up and disease experience in thyThe THYCA-QoL is a health-related quality of life questionnaire developed for thyroid cancer and thyroid cancer survivors using methodologically proven standard guidelines and validated questionnaires to improve symptoms, treatment, follow-up and disease experience in thyroid cancer survivors. roid cancer survivors.
Measured: At the end of Day 1, week 1, week 2, 1 month, 2 month, 3 month, 4 month, 6 month, 12 month
EORTC-QLQ-C30
It is a health-related questionnaire for cancer patients. It consists of 3 subdomains: overall quality of life, functional area, and symptom domain, a total of 30 items.
Measured: At the end of Day 1, week 1, week 2, 1 month, 2 month, 3 month, 4 month, 6 month, 12 month
BCQ
It is a dialectic tool that divides the physiological and pathological conditions and symptoms of the human body into three dialectics: concession, yinhe, and word-body, and identifies the deteriorated condition of the human body.
Measured: At the end of Day 1, week 1, week 2
CHPIQ
It is a key diagnostic technology that plays a decisive role in the selection of prescriptions in traditional Chinese medicine, and it is a symptom-based cold and heat pattern identification questionnaire that has been recognized for its reliability and validity. CHPIQ).
Measured: At the end of Day 1, week 1, week 2
MDASI-Core
The MDASI-core is a 19-item questionnaire that identifies pain, fatigue, nausea, vomiting, insomnia, shortness of breath, cognitive function, anorexia and dysthymia on a 10-point scale.
Measured: At the end of Day 1, week 1, week 2, 1 month, 2 month, 3 month, 4 month, 6 month, 12 month
Oral epithelial cell-based whole genome analysis
The Asia PMRA chip contains more than 300 cancer-related common variants and 2,600 rare variants as well as 2,600 pharmacogenomic-related variants, including more than 300 cancer-related common variants and 2,600 rare variants contained in the ClinVar (> 43,000 markers) or GWAS Catalog (> 23,400 markers), which are databases for diseases and various traits.
Measured: Day 1
overall survival
To investigate the overall survival of study subjects enrolled in the study and cancer-related deaths, from the time of initiation of cancer-related TCM treatment to death.
Measured: At the end of Day 1, week 1, week 2, 1 month, 2 month, 3 month, 4 month, 6 month, 12 month
Adverse events
CTCAE ver. To investigate the types and incidence of adverse events in accordance with 5.0.
Measured: At the end of Day 1, week 1, week 2, 1 month, 2 month, 3 month, 4 month, 6 month, 12 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Dec 2023
- Study start1 Dec 2023
- Primary completion31 Dec 2029 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Thyroid CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ilsan Cha hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jee Young Lee, CHA University
- Investigators
- Jee Youg Lee, Principal investigator, Ilsan Cha hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06158360
- Sponsor's protocol ID
- ICICC-OS-23-01
- Status last verified
- Mar 2026
- First submitted
- 6 Nov 2023
- Last updated
- 30 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Multi-centered Observational Study on Postoperative Symptoms After Thyroidectomy (POS-T) in Patients With Thyroid Cancer
- ClinicalTrials.gov ID
- NCT06158360
- Acronym / sponsor ID
- ICICC-OS-23-01
- Conditions
- Thyroid Cancer
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Ilsan Cha hospitalUniversity, hospital or other
- Study start
- 1 Dec 2023 (actual)
- Primary completion
- 31 Dec 2029 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 6 Dec 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This observational study aimed to evaluate the safety and efficacy of postoperative management in patients with thyroid cancer who received subtotal or total thyroidectomy.
Detailed description
- Characteristic analysis of improvement in quality of life and symptoms after surgery in cancer patients
- Multifaceted symptom evaluation of cancer patients visiting medical institutions
- Evaluation of effectiveness and safety of treatment for postoperative symptoms in thyroid cancer patients
- Analysis of the effectiveness and prognosis of cancer-related treatment for each patient with cancer
- Analysis of prognostic factors for disease-free survival and overall survival of cancer patients
Among adult men and women aged 19 years or older who have been diagnosed with thyroid cancer, who have undergone partial or total thyroidectomy and visited the hospital for postoperative management, the characteristics of the visiting patient, quality of life, characteristics of cancer-related symptoms, and treatment effectiveness, We intend to conduct a prospective observational study to evaluate safety and its relationship with prognosis. In addition, we aim to form the basis for follow-up research through the establishment of an Oriental medicine cancer cohort and database.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients who have been diagnosed with thyroid cancer (KCD C73) according to the ICD-10 International Classification of Diseases and have been recommended for postoperative management treatment by a physician or acupuncturist
Key inclusion criteria (6 listed)
- 19 years of age or older
- Those who have been confirmed to have a malignant tumor of the thyroid gland by biopsy or imaging
- Subjects who have undergone partial thyroidectomy or total resection within 1 month
- Those who have agreed to the implementation of Chinese medicine treatment
- The Eastern Cooperative Oncology Group(ECOG) performance status 0-3
Key exclusion criteria (5 listed)
- ○ When it is judged that other diseases other than cancer (dementia, cerebrovascular disease, severe organ failure, etc.) may have a significant effect on the decline of physical function
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
THYCA-QoL score at the time of discharge (1w) of hospitalization performed for postoperative management purposes
Time frame: At the end of week 1(each cycle is 7days)
The THYCA-QoL is a health-related quality of life questionnaire developed for thyroid cancer and thyroid cancer survivors using methodologically proven standard guidelines and validated questionnaires to improve symptoms, treatment, follow-up and disease experience in thyThe THYCA-QoL is a health-related quality of life questionnaire developed for thyroid cancer and thyroid cancer survivors using methodologically proven standard guidelines and validated questionnaires to improve symptoms, treatment, follow-up and disease experience in thyroid cancer survivors. roid cancer survivors.
8 secondary outcomes
Change in THYCA-QoL over time series
Time frame: At the end of Day 1, week 1, week 2, 1 month, 2 month, 3 month, 4 month, 6 month, 12 month
EORTC-QLQ-C30
Time frame: At the end of Day 1, week 1, week 2, 1 month, 2 month, 3 month, 4 month, 6 month, 12 month
BCQ
Time frame: At the end of Day 1, week 1, week 2
CHPIQ
Time frame: At the end of Day 1, week 1, week 2
MDASI-Core
Time frame: At the end of Day 1, week 1, week 2, 1 month, 2 month, 3 month, 4 month, 6 month, 12 month
Oral epithelial cell-based whole genome analysis
Time frame: Day 1
overall survival
Time frame: At the end of Day 1, week 1, week 2, 1 month, 2 month, 3 month, 4 month, 6 month, 12 month
Adverse events
Time frame: At the end of Day 1, week 1, week 2, 1 month, 2 month, 3 month, 4 month, 6 month, 12 month
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Mar 2026.
Related trials for Thyroid Cancer
Not yet recruitingPhase 1/2
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Thyroid Cancer
Not yet recruitingObservational study
Serum Treg/Th17-Related Cytokines and Systemic Inflammatory Indices in Differentiated Thyroid Cancer
Differentiated Thyroid Cancer (DTC), Papillary Thyroid Carcinoma
Recruiting
Ultrasound-guided Microwave Ablation of Benign Thyroid Nodules
Thyroid Nodule (Diagnosis)
Not yet recruiting
Endotracheal Tube Versus Transcartilage Needle Electrodes for Nerve Monitoring in Thyroid Surgery
Thyroid Diseases, Recurrent Laryngeal Nerve Injury
RecruitingPhase 2
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
Thyroid Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jee Youg Lee principal investigator
Ilsan Cha hospital
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Thyroid Cancer, run by Ilsan Cha hospital at 3 sites in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jee Youg Lee (082-31-782-3113, happiade@chamc.co.kr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
THYCA-QoL score at the time of discharge (1w) of hospitalization performed for postoperative management purposes (time frame: At the end of week 1(each cycle is 7days)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Mar 2026.